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a b s t r a c t
Prophylactic vaccines for human papillomavirus (HPV) are being introduced in many countries for the
prevention of cervical cancer, the second most important cause of cancer-related death in women glob-
ally. This is likely to have a signiﬁcant impact on the future burden of cervical cancer, particularly where
screening is non-existent or limited in scale. Previous research on the challenges of vaccinating girls with
the HPV vaccine has focused on evidence fromdeveloped countries.We conducted a systematic search of
the literature in order to describe the barriers and challenges to implementation of HPV vaccine in low-
and middle-income countries. We identiﬁed literature published post-2006 to September 2012 from ﬁve
major databases. We validated the ﬁndings of the literature review with evidence from qualitative key
informant interviews. Three key barriers to HPV vaccine implementation were identiﬁed: sociocultural,
health systems and political. A linked theme, the sustainability of HPV vaccines programmes in low-
and middle-income countries, cuts across these three barriers. Delivering HPV vaccine successfully will
require multiple barriers to be addressed. Earlier research in developed countries emphasised sociocul-
tural issues as the most signiﬁcant barriers for vaccine roll-out. Our evidence suggests that the range
of challenges for poorer countries is signiﬁcantly greater, not least the challenge of reaching girls for
three doses in settings where school attendance is low and/or irregular. Financial and political barri-
ers to HPV vaccine roll-out continue to be signiﬁcant for many poorer countries. Several demonstration
and pilot projects have achieved high rates of acceptability and coverage and lessons learned should be
documented and shared.
© 2013 The Authors. Published by Elsevier Ltd.   
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. Introduction
Prophylactic vaccines for human papillomavirus (HPV) prevent
ervical cancer, the second major cause of cancer-related deaths
mongst women in less developed countries [1,2]. Cervical can-
er causes approximately 275,000 deaths annually worldwide,
f which 88% occur in low income countries (LICs) [1,3] Imple-
entation of a primary prevention vaccine is likely to have a
igniﬁcant impact on the burden of cervical cancer, particularly
here screening isnon-existentor limited in scaleorofpoorquality
4].
HPV is the most common sexually transmitted infection (STI)
lobally, prevalent in approximately 11–12% of women and is the
ajor cause of cervical cancer [1,3]. There are over 100 types ofHPV
enotypes, with HPV types 16 and 18 being responsible for approx-
mately 70% of cervical cancers, and types 6 and 11 for 96–100% of
enital warts infections [3]. The relationship between cervical can-
er and HPV is often poorly recognised by both policymakers and
omen [5].
There are two commercially available prophylactic HPV vac-
ines [6,7]. At least 110 countries have licensed the bivalent HPV
accine (CervarixTM) that protects against HPV genotypes 16 and
8 and over 120 countries have licensed the quadrivalent vac-
ine (GardasilTM) that protects against HPV genotypes 6, 11, 16
nd 18 [8]. However, licensure does not mean that all these
ountries are currently providing the vaccine within the public
ector. The inclusion of the HPV vaccine into national immunisa-
ion programmes has varied widely; in 2012 of the 51 countries
mplementingnationalHPVvaccinationprogrammes, only sixwere
MICs. The number of smaller-scale or demonstration projects con-
inues to increase. Currently 26 low-, middle- and upper-middle
ncome countries are engaged in piloting activities to test deliv-
ry strategies, understand and overcome potential barriers and to
nform decision-making for future national roll-out of the vaccine
8–11].
The primary target group for HPV vaccination is girls aged 9–13
ears in order to vaccinate prior to the onset of sexual activity and
herefore before HPV is acquired, [12]. Although many Latin Amer-
ca andCaribbean, African countries andAsian LIC have been able to
each adolescent girls with single or multiple dose vaccines such as
epatitis B, measles or tetanus toxoid to prevent neonatal tetanus
13–15], some studies suggest that vaccinating pre-adolescents
<10 years) and adolescents (10–19 years) girls can be a public
ealth challenge [16,17]. The HPV vaccine, which requires multi-
le doses delivered to pre-adolescent girls and targets a sexually
ransmitted infection (STI), therefore presents unique delivery
hallenges [16].
Despite the HPV vaccine’s proven safety, efﬁcacy and cost-
ffectiveness there exists a signiﬁcant lag in its introduction in
able 1
haracteristics of key informants.
Key informant Type of organisation Position
A International NGO Program
B International funding agency Deputy D
C Local, country-based vaccination programme HPV Proj
D International funding agency Senior Pr
E Local country-based vaccination programme Epidemi
F International organisation Technica
G International organisation Medical. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3816
low- and middle-income countries (LMICs) [10]. In this study we
examined the barriers and challenges to implementation of HPV
vaccine in LMICs. As more countries consider its introduction, a
review of the lessons from pilot projects and programme roll-outs
in LMICs is essential to understand barriers to implementation and
sustainability of an HPV vaccine programme.
2. Materials and methods
This paper uses two research methods, a literature review that
preceded and informed subsequent key informant (KI) interviews.
For the literature review four databases (PopLine, PubMed, Web
of Science, Science Direct) were systematically searched with the
following title search terms: “human papillomavirus” OR “HPV”
AND “vaccine” OR “vaccination”. The database search was supple-
mented by a hand search of Google Scholar using the same title
search terms. The search was restricted to English language items
published since 2006, when the HPV vaccines became commer-
cially available, until September 2012 [18]. The search yielded 5597
items, of which 2564 were duplicates, producing 3033 English lan-
guage items published between 01/01/2006 and 30/08/2012 that
were screened on title and abstract. Articles focusing solely on evi-
dence from HICs were excluded. However, items that included a
mix of HICs and LMICs were included in the thematic analysis.
Country income groups were deﬁned using the World Bank classi-
ﬁcation [9]. Items were included in the results if they reported on
HPV vaccine implementation, including pilot projects, in LMICs. A
total of 41 items were included in the thematic analysis (Table 2).
Thematic analysis of the ﬁndings of the literature review preceded
identifying broad areas under sociocultural, health system and
political challenges as well as more speciﬁc issues including the
sub-topics. These ﬁndings informed the design of the KII question
guide. KIs explored themes that emerged from the literature review
and represent a snapshot of the challenges and barriers during the
vaccine implementation process.
A semi-structured interview guide was developed and KIs
shared thoughts through open-ended questions on what they
believed to be the greatest challenges to implementing the HPV
vaccine inLMICsandprovidedperspectiveon themajor themesand
sub-sections that emerged from the literature review results. For-
mative research studies identiﬁed similar barriers to consider and
overcome for the vaccine’s introduction and supported the selec-
tion of themain themeswithin the literature review [11,19]. A draft
interview guide was reviewed by individuals working in reproduc-
tive health at an international organisation to strengthen its face
validity [20]. One of the authors (DW-J) was originally interviewed
as a KI, prior to subsequent involvement in this paper, and did not
inﬂuence selection of quotes for inclusion. The interview guides
are available from the corresponding author. Ethical approval for
held Region of expertise
me Manager International; works in LIC and LMIC (Africa and Asia)
irector International
ect Coordinator Sub-Saharan Africa; LIC
ogramme Ofﬁcer International
ologist Sub-Saharan Africa; LIC
l Ofﬁcer International
Ofﬁcer International
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his research was received from the London School of Economics,
nd informed consent was obtained from each KI after the nature
nd possible consequences of the research were explained. KIs gave
ritten consent for anonymous quotes to be included in this paper.
even interviews were conducted by the corresponding author
July 2011) using audio conference, each lasting between 20 and
0 min. We  used the Internet to identify and contact key individ-
als working in the vaccine ﬁeld as identiﬁed in key reports and
ournal articles. Four of the KIs were purposively selected for their
esearch, policy or practical experience within HPV vaccines. Fif-
een individuals were contacted from a range of non-governmental
nd international organisations and those implementing national
PV vaccine programmes and demonstration projects. Four refused
nd four did not respond to the request. KIs were not compen-
ated for their participation. Characteristics of the KIs are described
roadly in Table 1 in order to preserve their anonymity. Interviews
ere conducted in English, digitally recorded with permission,
ranscribed verbatim and anonymised. Interviews were analysed
ndividually to identify overarching themes and were manually
oded to assess each interview for topics and dissonance between
nformants [21].
. Results
Items identiﬁed by the search included studies and experiences
rom individual countries (Peru, Vietnam, Uganda, India, Rwanda,
hana, Tanzania, Malaysia, Indonesia, Kenya, Bhutan, Bolivia, Cam-
odia, Haiti, Lesotho and Nepal) and broad world regions. Three key
arriers to the implementation of HPV vaccination in LMICs were
dentiﬁed in the literature review: sociocultural, health system and
olitical (Table 2) and were supported by KIs. The sustainability of
PV vaccine programmes was identiﬁed as a cross-cutting chal-
enge in the literature.
. Sociocultural barriers
Sociocultural barriers to implementing the HPV vaccine iden-
iﬁed in the literature are outlined in Table 2. Six of seven KIs
ighlighted potential issues to inﬂuence uptake and coverage of
accine including: lack of knowledge amongst parents, cultural tra-
itions and rumours. Communicating on the vaccine’s preventive
urpose and the need to provide adequate sensitisation at all lev-
ls were highlighted by both literature and KIs as important to
vercome sociocultural barriers.
Despite theories that LMIC communities might express con-
erns about targeting only female adolescents to prevent an STI
nd the potential for social stigma, studies and KIs found that these
oncerns were rare [26,38,40–42].
“Amazingly, I don’t think that there were as many barriers as we
were expecting at the beginning.”  (KI-G).
able 2
ummary of challenges identiﬁed in literature.
Sociocultural Health system & logi
Low knowledge of HPV and its relation to cervical cancer
[22–27]
Infrastructure and hu
Societal values and stigma [38–42] Financing Mechanism
[23,28,33,35,36,39,43
Parental concerns of side effects including (in)fertility,
early sexual onset, increased sexual activity and vaccine
safety [23,24,26,27,31,48,50]
Donation Programme
Vaccine target age and group [26,29,42,57] Reaching out-of-scho
Community sensitisation and advocacy
[26,31,36,39,41,42,59,60]
Logistics and timetab
Delivery Strategies [3 (2013) 3811– 3817 3813
“There’s going to need to be a very broad sensitisation plan that
involves lots of different potential parties including the stakeholders
but also groups, like religious groups etc.” (KI-E).
Parental concerns within the literature focused on fear of future
(in)fertility, increased and/or earlier sexual activity and the safety
of the vaccine [23,24,26,27,48,58]. In Kenya, although baseline
knowledge of cervical cancer, screening and the HPV vaccine
were low, following information and communication about vaccine
beneﬁts, 95% of mothers reported that they would vaccinate their
daughters [22]. Similar ﬁndings were reported in Ghana, Tanza-
nia and Indonesia [23–25]. Several studies from LMICs report on
the intention to vaccinate, rather than actual acceptance of vaccine
[23,40–42]. However, recent experiences from vaccination demon-
stration projects and the national roll-out of HPV vaccine in Rwanda
have reported success in reaching their primary target group
with high coverage for all three doses and overcoming concerns
regarding vaccinating adolescents against an STI [40–42,45,57,58].
The need for information about the dual preventive capacity of
the HPV vaccine as both an STI and cervical cancer vaccine was
viewed as essential to mitigating sociocultural issues by one KI.
“There is a debate on whether it should be introduced as an STI
vaccine or a cancer vaccine. . .and sometimes you hear that it’s
easier to say that it is a cancer vaccine because it doesn’t face as
much taboo or debate, as does sexual health issues. . .Ideally it could
be presented as a cancer vaccine, and little by little, it should be
explained to the community but mainly to the target population
that the vaccines protect against an infection due to HPV and that
it is an STI” (KI-G).
Timing of introducing the vaccine was identiﬁed by three KIs as
important in order to avoid launching before conducting adequate
community sensitisation, which could result in increased misin-
formation and low uptake. Education and sensitisation at all levels
was essential to increase knowledge about cervical cancer and HPV,
to mitigate sociocultural barriers was  outlined in several studies
[26,31,36,39–42,60] and by six KIs
5. Health system barriers
Insufﬁcient infrastructure and human resources [28–31],
ﬁnancing, donation programmes and the delivery method were
identiﬁed as signiﬁcant health system barriers both within the lit-
erature and by all seven KIs.
5.1. Infrastructure & human resourcesAll seven KIs identiﬁed vaccine cold storage and one KI out-
lined the number of dosages as challenges to implementing the
HPV vaccine in LMICs:
stical Political
man resources [28–31] Lack of political will [28,32–37]
s and Vaccine Cost
–48]
Involvement and coordination of
diverse stakeholders [13,35,43,49]
s [36,40–42,51–54] Competing health priorities and
evidence-based decision-making
[29,32–35,37–39,55,56]
ol girls [26,30,31,38,40,42,57,58]
ling [28,60]
0,31,38,40–42,57–61]
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“If we could have the vaccine without needing the cold chain, that
would be great. So reducing doses and reducing our reliance on the
cold chain, those are the general directions we would like to see it
go”  (KI-F)
Logistical issues at the health provider level in particular for
ransporting staff and vaccines were obstacles, in part because of
he large quantities of vaccine vials needed were identiﬁed by three
Is:
“In terms of the vaccine itself. . .it’s a single vial vaccine, and it takes
up a lot of space” (KI-E).
Insufﬁcient human resources and capacity of staff were also
eported as a challenge to vaccine delivery by three KIs:
“Even before introducing this HPV vaccine we had limited health
workers, especially those that are working in reproductive health
clinics. . .adding HPV on top of all they are doing, they are already
overwhelmed.” (KI-C).
“Adding the HPV vaccine. . .is  a little bit complicated vaccine as
compared to other vaccines because most other vaccines are done
at the health care facility, but this one, the nurse, the health worker
has to travel to the schools” (KI-C).
.2. Financing mechanisms
Financing for the HPV vaccine was reported as a signiﬁcant chal-
enge by all seven KIs and within literature [23,28,33,34,43,48,62].
he vaccine cost ranges from US$13 to more than US$100 for
ach dose to the public sector, making this unaffordable for many
MICs [45]. Progress has, however, been made through ﬁnancing
echanisms, such as the GAVI Alliance (formerly known as the
lobal Alliance for Vaccines and Immunisation) or the Pan Ameri-
an Health Organization (PAHO) Revolving Fund for Latin America
nd Caribbean countries [35]. The GAVI Alliance aims to improve
ccess of eligible LICs to vaccines through negotiating lower vac-
ine prices and co-ﬁnancing, until countries can afford the vaccines
44]. In June 2011, Merck and Co., announced that vaccines will
e provided to GAVI Alliance for $5 USD per dose [46,47]. The
AVI Alliance has now opened the window for eligible countries to
eceive support to implement demonstration projects or to support
ational programmes for countries that already have experience
ith delivering the vaccine. However, countries including many
MICs with a gross national income of more than $1550 per capita
re not eligible for GAVI support [45].
Although increased priority and decreased price represent
rogress, reaching the large female adolescent population for three
osages is expensive. Five KIs identiﬁed other costs to start-up and
ustain programmes as additional issues:
“GAVI’s announcement is not a panacea, it is one component of
the ﬁnancial barriers that then get broken down but these other
components related to funding start-up costs and some onward
implementation costs could be a potential barrier for countries”
(KI-A).
“The initial cost is very challenging. . .I’m not talking about the cost
to buy the HPV vaccine. . .but the cost to take care of the necessary
logistics.” (KI-C).
.3. Donation programmes
Programmes such as the GARDASIL Access Program (GAP),
mplemented through Axios Healthcare Development with vaccine
onated by Merck, were established to donate limited amounts of
he vaccine to countries for demonstration projects to test HPV
accine delivery strategies [36,51]. Such pilot programmes suggest (2013) 3811– 3817
that in-country ownership and capacity development may  con-
tribute to long-term success and sustainability of vaccine delivery
[40–42]. Four KIs discussed donation programmes and challenges
to sustaining efforts long-term.
“There’s the perfect trifecta for sustainability. You need money, you
need political will and you need capacity. And until countries get
fully supported on all three of those it’s difﬁcult for any program to
be sustainable over time, and everybody has a role to play in that”
(KI-A).
Larger vaccine donations by GAP and the Merck Qiagen Initiative
has also permitted several LICs to start national roll-out of HPV
vaccine, including Rwanda [52,54]. Two  KIs highlighted the issue
of sustainability after the conclusion of these large-scale donation
programmes:
“It’s what’s going to happen at the end of that, that is critical,
because by that point the whole population has been through this
intervention, probably over a couple of years” (KI-E).
“You don’t want to see [countries] put in time, energy and effort
into something that can’t continue, and it’s disruptive to the other
services if it’s not well-planned” (KI-F).
5.4. Delivery methods
Reaching adolescent girls to deliver vaccines and other health
interventions was  reported as a signiﬁcant challenge. Demonstra-
tion projects and national programmes of HPV vaccine delivery
found that several vaccine delivery methods including school-
based programmes, at health-centres and the use of campaign
approaches, were successfully employed to achieve coverage
higher than that of many HICs, such as the United States, Denmark
or the Netherlands [30,52,57,58,60].
For school-based vaccine programmes, the two KIs working in
a LIC said poor timetable planning and documentation were con-
cerns as these could result in missed dosages, decreasing vaccine
coverage and overall programme success:
“It’s not just a one-off visit once a year, they’ve got to get in three
days just within the school calendar year” (KI-E).
“It is a big challenge to adequately and effectively document the
accepted names and the numbers of girls who  received dose one,
who received dose two and who received dose three” (KI-C).
School absenteeism was the primary reason for not being vacci-
nated in programmes in India, Peru and Uganda and in government
schools in Tanzania, although school attendance was reported to
be very high in all countries, suggesting school-based methods are
appropriate but measures are needed to capture pupils absent on
the day of vacccination [57,58].
Inadequate school-based health programmes was highlighted
by one KI as a potential threat to this delivery strategy [61]:
“There is in theory a school-based health program but in practice it
functions rather piecemeal. In practice some of those aspects of the
school health program have been very fragmented, so the tetanus
immunisation that is supposed to happen to girls aged about 15 in
schools, basically often doesn’t take place” (KI-E).
Two KIs suggested programmes might offer opportunities for
other age-relevant services such as de-worming or nutritional
supplements. This integrated approach is supported by the GAVI
Alliance for countries applying for GAVI Alliance support and rep-
resents an opportunity to reduce the cost and burden on health
systems of delivering separate interventions [45].
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Out-of-school girls were reported in the literature review as a
hallenge, especially in countries with lower school enrolment and
ttendance [26,30,31,38,40,42,57,58].
“Many women who are pregnant do bring their child once to some
sort of clinic, and they get sort of captured, for infant stuff, but you
know setting-up and sustaining school-based and out-of-school
youth vaccination programmes is quite complex and. . .I  don’t think
one size will ﬁt all here” (KI-E).
Introduction of the HPV vaccine in India assessed the ability
o reach this cohort through existing routine immunisation pro-
rammes or special campaigns (e.g. polio vaccines), and found a
ampaign approach at ﬁxed times achieved high coverage [58]. The
se of school-based programmes in combination with existing child
ublic health days was used in Uganda to reach out-of-school girls,
chieved 52.6% coverage, although the use of age as an eligibility
riteria was found to decrease coverage as opposed to the deliv-
ry method [42,50,63]. Vietnam tested two delivery strategies, the
chool-based strategy achieved 83.4% in its ﬁrst year and 93.4%
n its second year, while the second strategy using community
ealth centres achieved high coverage of 92.8% in its ﬁrst year and
8.00% in its second, for all three doses [31]. In Rwanda, commu-
ity involvement to identify girls who were either absent from, or
ot enrolled in school, combined with a national sensitisation cam-
aign prior to delivery of the ﬁrst dose, achieved over 93% coverage
or all rounds of vaccination [52]. GAP in seven countries, including
hutan, Bolivia, Cambodia, Haiti, Lesotho and Nepal, achieved aver-
ge coverage of 88% for all three doses using school, health facility
nd mixed methods of delivery [60].
. Political barriers
The literature and KIs identiﬁed a number of themes related
o the political barriers and facilitators focusing on political will,
oordinating stakeholders and competing health issues.
.1. Political will
Lack of political commitment to new health technologies was
dentiﬁed as an important challenge to successful implementa-
ion of HPV vaccine programmes [28,32]. Expensive, new public
ealth interventions, such as the HPV vaccine, demand more
ost-effectiveness and sustainability evidence in order to con-
ince policymakers [33,34]. It has been reported that decisions
n health priorities and the introduction of new vaccines should
e made nationally, based on evidence reﬂecting country-speciﬁc
urden [34]. However, in practice, it is feared that international
riorities, pharmaceutical company donations or subsidised vacci-
ation programmes, such as the GAVI Alliance, inﬂuence political
ommitment and decision-makers to embark on HPV vaccina-
ion programmes [35]. Two KIs also highlighted the challenging
ecision-making process and the role of political priorities versus
aking decisions based on country-speciﬁc evidence.
“We should be allowing countries to make a selection [of what to
prioritise] and GAVI should reﬂect that. That prioritization within
country plans and countries should be making decisions about
[whether to fund] vaccines versus other non-health opportunities”
(KI-B).
“In [country], we know it was the President, it was an election year,
and he decided or had been persuaded that this was a good thing
to do for [country] girls and women” (KI-F).
“I think that HPV unfortunately has taken an approach where it’s
played to some of the political needs.  . .grasped by some of the polit-
ical issues associated with HPV and risen to prominence. It may not (2013) 3811– 3817 3815
be driven by evidence. . .it may be more driven by political priorities
and the interests of a few champions” (KI-B).
6.2. Involvement of stakeholders
The diverse group of stakeholders, including sexual and repro-
ductive health, adolescent health, immunisation and cancer control
groups, is unique to HPV [13]. Coordinating different stakehol-
ders, each with their own  priorities, was seen as an impediment
to evidence-based decision-making and could also lead to compe-
tition of resources [35,43].
“What’s most important for sustainability is ensuring that every-
body that has a role to play in that, plays the role that they’re best at
and provides the support that’s needed, especially for the countries
that need it the most” (KI-A).
Three KIs recognised the importance of stakeholder knowledge
and approval.
“We have to involve all the subgroups of the community because
they all have to understand, they all have to agree” (KI-C).
The HPV vaccine has progressed relatively rapidly through
research and development and commercial availability [49]. Four
KIs, primarily from international perspectives, attributed this
success to cervical cancer advocacy groups, and suggested that
advocacy will continue to play a key role in inﬂuencing implemen-
tation and policymakers:
“I think cervical cancer advocacy has been quite good. . .they’ve
been able to mobilize themselves quite effectively and the vaccine
certainly has moved through its systems of development quite fast”
(KI-E).
6.3. Competing health priorities
Recognising HPV as a worthy cause of a country’s limited
resources, in comparison to other interventions, is one of the most
important barriers to implementation and sustainability within the
literature that must be conquered and was  highlighted within much
of the literature [29,38] and by all KIs.
“It’s hard to get decision-makers to prioritise an intervention that
is so costly, when they have others, such as trying to achieve the
MDGs, for under-ﬁves and so on. Where do you put that money
when you don’t have enough of it anyway?” (KI-F).
“It’s a women’s disease, it’s sexually transmitted – that’s a hard sell
for some cultures” (KI-F).
“It’s not a question of can we implement HPV vaccines and should
it be a public health priority, but that we would be remiss if we
didn’t make it a public health priority, we would be remiss in
our obligations to those countries and those communities. . .now
that we know that something works, you really do have a moral
obligation. . .”  (KI-A).
Evaluation of vaccine priorities need to examine not only
cost-effectiveness but also the affordability and distributional
equity in country-speciﬁc settings. Weighing the beneﬁts, costs
and cost-effectiveness of the HPV vaccine to other interventions,
such as the rotavirus vaccine, found similar number of lives
saved over each target populations’ lifetime, despite targeting
of different populations [55]. Two  KIs felt that the prioritisation
of the HPV vaccine is a challenge as a result of its delayed
impact:
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“It would be very difﬁcult to compare say a measles vaccine against
an HPV vaccine, where you see the immediate effect of the measles
vaccination, but your investment in HPV is much deferred” (KI-F).
“It kind of depends on whether you want to save lives right now or
save lives in the future”  (KI-D).
LMICs that have not yet introduced comprehensive cervical can-
er prevention strategies will have to consider whether it is feasible
o invest in both screening and vaccination [56]. One KI reported
stablishing a comprehensive cervical cancer approach,
“. . .was more challenging than we originally, perhaps naively
thought, because you’re working with different programmes, you’re
working with different target groups, and so while I think overall
the introduction of the vaccine allows an opportunity to have a
look at what your cervical cancer programme could consist of, it’s
difﬁcult to roll those things out, the sequencing does not have to be
simultaneous” (KI-F).
. Discussion
This study combines qualitative research with a review of cur-
ent literature on the challenges and prospects to implementing the
PV vaccine in low- and middle-income countries. This research
elps to document and share early experiences of the HPV vaccine
n LMICs to enable countries, considering introducing national or
emonstration programmes to build upon these lessons and estab-
ish best practices. The impact of timely implementation of the HPV
accine within LMIC will be substantial, as every ﬁve-year delay in
oll-out contributes to 2 million cervical cancer deaths [32].
This study has several limitations. The literature review only
ncluded items with English abstracts, so potentially relevant
esearch from non-Anglophone settings were excluded. The small
umber of KIs may  limit the generalisability of ﬁndings, however
arying in-country and international perspectives were repre-
ented. The rapid change in the ﬁeld of HPV vaccine policies and
rogrammes means that this study represents only a snapshot in
ime of the early experiences and that continued progress has likely
een achieved since conducting interviews. Although the major-
ty of KIs were not part of the country immunisation programmes,
hree of the seven KIs worked directly with health providers and
ational immunisation teams through demonstration and pilot
tudies shaping future national strategies and programme deci-
ions.
Finally, we present our ﬁndings from LICs and MICs together
ecause of the relatively small number of studies and KIs for each
ountry income group, and because of the cross-cutting themes
hat emerged from our thematic analysis. Early research from HICs
nd theoretical acceptance studies in LMICs predicted sociocul-
ural issues as the most signiﬁcant barrier for vaccine programmes,
lthough targeted sensitisation programmes have been successful
o overcoming this challenge and to achieving high vaccine accept-
bility and coverage rates in several LMIC. Our study identiﬁed
ealth system challenges and political issues in LMICs as areas that
epresent the most signiﬁcant challenges.
Health system barriers may  undermine the ability of some LMICs
o effectively implement high-quality HPV vaccine programmes.
ecuring sustainable ﬁnancing for the vaccine including health sys-
em costs and maintaining donation programmes, represents a
igniﬁcant obstacle. A record low price for as little as US $4.50 per
ose for LICs compared to more than $100 in HICs, was  announced
n May  2013, by the GAVI Alliance [64]. This reduced price and sup-
ort system of co-payments by GAVI Alliance will further increase
he affordability for LICs, however many MICs may  still experience
bstacles to funding and sustaining HPV vaccination programmes. (2013) 3811– 3817
The HPV vaccine has been described as a unique interven-
tion compared to other routine vaccination programmes, due to
the multifaceted barriers experienced. In particular, administering
three doses to girls 9–13 years, a new target group not previously
reached by routine immunisations in most countries highlights
obvious infrastructure and cold chain challenges. Reaching this
cohort through special campaigns and school-based delivery meth-
ods may  not be ﬁnancially feasible or sustainable considering the
additional and on-going costs to current immunisation structures
[65–67]. This vaccine also raises novel political issues, in particu-
lar the coordination of multiple stakeholder groups. Robust local
evidence and education about cervical cancer will be essential to
garnering the necessary political support to roll-out vaccination.
Currently neither HPV vaccine has been licensed for girls less
than 9 years of age, following the WHO  recommendations tar-
get age range [18]. Continued research is needed on the period
of immunogenicity provided by the vaccine and the possibility of
reducing the number of doses without affecting vaccine efﬁcacy
[68].
Considerable progress has been made in several LMIC and it
is important to understand lessons that are transferable to other
settings. School-based programmes have been successful but alter-
native and innovative sensitisation and delivery methods will be
important for achieving more equitable delivery. Demonstration
and pilot projects in several LMICs have shown that methods
including delivery through schools, special campaign, health cen-
tres or a multiple methods can reach a large proportion of eligible
girls and that advocacy and sensitisation is essential.
GAP countries including Cameroon, Lesotho and Uganda have
recently shared lessons from pilot activities including the impor-
tance of garnering political commitment, mobilising resources and
recommending integrating the vaccine within existing immunisa-
tion structures for sustainability [69]. An evaluation of eight GAP
pilots found that delivery through mixed-models in both schools
and health facilities as most effective [60]. However, the authors
acknowledge, that implementation of HPV vaccination needs to
be adapted to local priorities, and that successful demonstration
projects do not equate to a one-size-ﬁts all for other LMICs. The
results of HPV vaccine experiences so far in LMIC are encourag-
ing and continued sharing of evidence, successes and challenges is
critical to the replicability of successful HPV vaccine interventions
worldwide.
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